Economic impact simulation analysis of use of tigecycline, as appropriate, in first-course antibiotic therapy for complicated intra-abdominal infections in intensive care patients - PubMed (original) (raw)
. 2010 Oct;101(5):319-28.
Affiliations
- PMID: 21048554
Economic impact simulation analysis of use of tigecycline, as appropriate, in first-course antibiotic therapy for complicated intra-abdominal infections in intensive care patients
F Ancona. Minerva Med. 2010 Oct.
Abstract
Aim: Tigecycline is a broad spectrum antibiotic indicated by official and health ministry guidelines for use in second course therapy for complicated intra-abdominal infections (cIAI). In certain objective and subjective circumstances, however, its use in first-line therapy may be appropriate. Without entering into a detailed evaluation of use appropriateness, the aim of this study was to determine the economic impact on hospital budget expenditure for two different prescribing practices: use of tigecycline in second or first-line therapy. This empirical study was carried out at the Intensive Care Unit (ICU) (chief, Dr. Alberto Costantini), Ospedali Riuniti, Ancona.
Methods: Cost determination was based on health care processes as revealed by field survey at the ICU. Mapping of the health care processes was not derived from official protocols or from an ex post analysis of medical records but rather directly from descriptions of the processes as referred by the ICU physicians and health care staff, and then summarized in flow charts and approved by the ICU chief.
Results: The assumption was that tigecycline, because it has a broader spectrum of action than a first-line antibiotic, would more probably clear infections when used in the first course of antibiotic therapy. Notwithstanding this advantage, tigecycline has a higher daily dose cost than first-line antibiotics. This study compared the higher costs incurred by the use of tigecycline as a first-line antibiotic versus potential savings obtained with such use, also in view of the prevention of possible treatment failures and the additional cost of administering a second course of antibiotic therapy, wherein the result would depend on the number of preventable treatment failures.
Conclusion: The analysis concludes with a discussion and graphic illustrations comparing the differential probable treatment success which would render the two treatment alternatives economically indifferent.
Similar articles
- What role for tigecycline in infections?
BMJ Group. BMJ Group. Drug Ther Bull. 2008 Aug;46(8):62-4. doi: 10.1136/dtb.2008.07.0018. Drug Ther Bull. 2008. PMID: 18687585 Review. - Cost of Gram-negative resistance.
Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, Schulman AR, Hughes MG, Raymond DP, Pruett TL, Sawyer RG. Evans HL, et al. Crit Care Med. 2007 Jan;35(1):89-95. doi: 10.1097/01.CCM.0000251496.61520.75. Crit Care Med. 2007. PMID: 17110877 - Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit.
Swoboda S, Ober M, Hainer C, Lichtenstern C, Seiler C, Wendt C, Hoppe-Tichy T, Büchler M, Weigand MA. Swoboda S, et al. J Antimicrob Chemother. 2008 Mar;61(3):729-33. doi: 10.1093/jac/dkm541. Epub 2008 Jan 25. J Antimicrob Chemother. 2008. PMID: 18222953 - Tigecycline: a critical analysis.
Stein GE, Craig WA. Stein GE, et al. Clin Infect Dis. 2006 Aug 15;43(4):518-24. doi: 10.1086/505494. Epub 2006 Jun 26. Clin Infect Dis. 2006. PMID: 16838243 Review.
Cited by
- Multiresistant bacteria and current therapy - the economical side of the story.
Wilke MH. Wilke MH. Eur J Med Res. 2010 Nov 30;15(12):571-6. doi: 10.1186/2047-783x-15-12-571. Eur J Med Res. 2010. PMID: 21163732 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical